TKT and glioblastoma: However, pharmacokinetic factors such as low transduction efficiency may limit the success of this approach as indicated by the results of the herpes simplex virus-thymidine kinase gene/ganciclovir (HSV-TK/GCV) trial on glioblastoma multiforme [23].